Brian Cheng
Stock Analyst at JP Morgan
(1.76)
# 3,174
Out of 4,884 analysts
65
Total ratings
34.62%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Downgrades: Neutral | $130 → $129 | $128.35 | +0.51% | 3 | Jun 2, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $15 → $8 | $10.18 | -21.41% | 4 | May 13, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $41 | $26.90 | +52.42% | 1 | May 2, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $42.85 | - | 1 | Mar 27, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $51.05 | +11.66% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $10.74 | +21.04% | 4 | Feb 28, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $4.46 | - | 2 | Jan 30, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $2.57 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $13.04 | +38.04% | 2 | Dec 16, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $8.42 | +232.54% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $46 | $16.95 | +171.39% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $2.81 | +1,074.38% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.67 | +259.28% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $8.84 | +171.49% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.62 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $0.29 | +1,627.12% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.19 | +572.27% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $10.99 | +36.49% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.38 | +3,622.41% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $2.85 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.61 | +888.47% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.20 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.24 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $13.78 | +516.84% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $8.94 | +134.90% | 1 | Aug 3, 2021 |
Blueprint Medicines
Jun 2, 2025
Downgrades: Neutral
Price Target: $130 → $129
Current: $128.35
Upside: +0.51%
iTeos Therapeutics
May 13, 2025
Downgrades: Neutral
Price Target: $15 → $8
Current: $10.18
Upside: -21.41%
CG Oncology
May 2, 2025
Initiates: Overweight
Price Target: $41
Current: $26.90
Upside: +52.42%
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $42.85
Upside: -
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $51.05
Upside: +11.66%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $10.74
Upside: +21.04%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $4.46
Upside: -
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.57
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $13.04
Upside: +38.04%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $8.42
Upside: +232.54%
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $16.95
Upside: +171.39%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $2.81
Upside: +1,074.38%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.67
Upside: +259.28%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $8.84
Upside: +171.49%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.62
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $0.29
Upside: +1,627.12%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.19
Upside: +572.27%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $10.99
Upside: +36.49%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.38
Upside: +3,622.41%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $2.85
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.61
Upside: +888.47%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.20
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.24
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $13.78
Upside: +516.84%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $8.94
Upside: +134.90%